Insulet raised its 2026 revenue growth forecast to a range of 21% to 23% following a first-quarter earnings beat on Wednesday. The medical device maker previously projected growth between 20% and 22% as demand for its tubeless insulin pumps accelerates. This revision signals successful capture of the expanding diabetes technology market.
Insulet Raises Revenue Outlook After Quarterly Beat
Insulet raised its 2026 revenue forecast following strong quarterly results. Demand for Omnipod 5 pumps drove revenue to $761.7 million, beating expectations.
Xurve View
洞察:
Xurve View










